Hereditary Diffuse Gastric Cancer Syndrome and the Role of CDH1 A Review

IMPORTANCE Inherited variants in the tumor suppressor gene CDH1 are associated with an increased risk of gastric and breast cancers. This review aims to address the most current topics in management of the hereditary diffuse gastric cancer syndrome attributed to CDH1. OBSERVATIONS Consensus management guidelines have broadened genetic testing criteria for CDH1. Prophylactic total gastrectomy is recommended for any pathogenic or likely pathogenic CDH1 variant carrier starting at the age of 20 years. Annual surveillance endoscopy is recommended to those who defer prophylactic total gastrectomy. Women with a CDH1 variant should initiate magnetic resonance imaging breast surveillance starting at age 30 years. Further research is needed to understand the pathogenesis of early-stage gastric cancers (T1a), which are pathognomonic of hereditary diffuse gastric cancer syndrome, that lead to advanced gastric cancer to develop both treatment and prevention strategies for this patient population. CONCLUSIONS AND RELEVANCE The heritable CDH1 gene mutation is of importance to today's surgeons because it is associated with a substantial increased risk of developing both gastric and breast cancers. Management of this cancer syndrome currently uses prophylactic surgery and enhanced cancer surveillance strategies.

Automated summary

Inherited variants in the CDH1 tumor suppressor gene are associated with increased risk of gastric and breast cancers. Current management strategies for the hereditary diffuse gastric cancer syndrome include prophylactic surgery and enhanced cancer surveillance. Further research is needed to understand the pathogenesis of early-stage gastric cancers and develop effective treatment and prevention strategies for this population.